Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00913497 · ClinicalTrials.gov registry record · Phase 4
The Effect of Insulin Glulisine Compared With Insulin Aspart on Breakfast Post Prandial Glucose Levels in Prepubertal Children
A Phase 4 study of Type 1 Diabetes Mellitus, sponsored by Corewell Health West.
- Completed
- Registry status
- Phase 4
- Development phase
- 16
- Enrollment target
- 1
- Study location
NCT00913497 is a Phase 4 study of Type 1 Diabetes Mellitus that has completed, run by Corewell Health West. The registered enrollment target is 16 participants, below the 140-participant average among 105 other Type 1 Diabetes Mellitus trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00913497, a Phase 4 study of Type 1 Diabetes Mellitus, has completed, sponsored by Corewell Health West.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 16 participants
- Enrollment target
- 1
- Study location
Study Summary
To determine whether insulin glulisine decreases the breakfast post prandial glycemic excursion in comparison to insulin aspart.
Conditions Studied
Interventions
- DRUG insulin aspart
- DRUG insulin glulisine
Study Locations (1)
Michigan
- Helen DeVos Childrens Hospital - Grand Rapids
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2009-06 |
| Est. Completion | 2012-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00913497
The ClinicalTrials.gov registry entry for NCT00913497 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 140-participant average among 105 other Type 1 Diabetes Mellitus trials with a reported enrollment target (89% lower). The listed sponsor is Corewell Health West, which has 38 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Type 1 Diabetes Mellitus appearing as the primary indexed condition, and to 2 interventions - of which insulin aspart is the first listed.
NCT00913497 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.
Frequently Asked Questions
What is clinical trial NCT00913497 about?
NCT00913497 is a clinical study titled "The Effect of Insulin Glulisine Compared With Insulin Aspart on Breakfast Post Prandial Glucose Levels in Prepubertal Children". To determine whether insulin glulisine decreases the breakfast post prandial glycemic excursion in comparison to insulin aspart.
What is the current status of trial NCT00913497?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 16 participants. The study started on 2009-06. Estimated completion is 2012-01.
What conditions does trial NCT00913497 study?
This clinical trial studies the following conditions: Type 1 Diabetes Mellitus.
What interventions are being tested in trial NCT00913497?
The interventions under investigation include: insulin aspart (DRUG), insulin glulisine (DRUG).
Who is sponsoring clinical trial NCT00913497?
This trial is sponsored by Corewell Health West, which has 38 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00913497 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 1 Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Dapagliflozin Plus Pioglitazone in T1DM
RECRUITING · Phase 4
-
CONSISTENT 1: Metabolic and Safety Outcomes of Hylenex Recombinant (Hyaluronidase Human Injection) Preadministered at CSII Infusion Site in Participants With Type 1 Diabetes Mellitus (T1DM)
COMPLETED · Phase 4
-
Effect of Ethanol Intoxication on the Anti-Hypoglycemic Action of Glucagon
COMPLETED · Phase 4
-
Detemir: Role in Type 1 Diabetes
COMPLETED · Phase 4
-
Evaluate Use of Tropocells(R) Autologous Platelet-rich Fibrin (PRF) for Wagner Grade 1 and Grade 2, Mild to Mod Neuroischemic Plantar Diabetic Foot Ulcer Wound Care.
RECRUITING · Phase 2
-
Subcutaneous Pharmacokinetic Evaluation of Monomeric Insulin and Lyumjev in Adults With Type 1 Diabetes
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.